In addition, the reduction of serum KL-6 level after CTX pulse therapy presents itself as a supporting indicator for treatment effectiveness in the CTD-ILD patients in combination with other diagnostic biomarkers. This evidence concerns the gene MUC1 and interstitial lung disease.